Clinical Trial: Subconjunctival Bevacizumab and Recurrent Pterygium

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium

Brief Summary: A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Detailed Summary:

  1. Pacients with recurrent pterygium
  2. Anti-VEGF therapy -Bevacizumab

Sponsor: Instituto de Olhos de Goiania

Current Primary Outcome: Pterygium size after subconjunctival bevacizumab [ Time Frame: 8 weeks ]

-Size of recurrent pterygium (measured in mm) after injection


Original Primary Outcome: Same as current

Current Secondary Outcome: Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 8 weeks ]

-Number of patients with hyposphagma and irritative symptoms after subconjunctival injection


Original Secondary Outcome: Same as current

Information By: Instituto de Olhos de Goiania

Dates:
Date Received: November 29, 2012
Date Started: February 2012
Date Completion:
Last Updated: December 6, 2012
Last Verified: December 2012